Page 109 - 202004

2012，68（5）：671-680. of intestinal CYP2C19 genotypes on the interaction be-
[ 2 ] 朱琳，宋洪涛，王庆华，等.肾移植受者他克莫司的血药浓 tween tacrolimus and omeprazole，but not lansoprazole，in
度与 CYP3A5*3 基因多态性的关系[J].中国临床药学杂 adult living-donor liver transplant patients[J]. Drug Metab
志，2012，21（4）：201-204. Dispos，2009，37（4）：821-826.
[ 3 ] EVANS WE，MCLEOD HL. Pharmacogenomics-drug dis- [17] BOSÓ V，HERRERO MJ，BEA S，et al. Increased hospital
position，drug targets，and side effects[J]. N Engl J Med， stay and allograft disfunction in renal transplant recipients
2003，348（20）：538-549. with CYP2C19 AA variant in SNP rs4244285[J]. Drug
[ 4 ] CHEN P，LI J，LI J，et al. Dynamic effects of CYP3A5 po- Metab Dispos，2013，41（2）：480-487.
lymorphism on dose requirement and trough concentra- [18] 赵水瑜，刘红霞，郑青山，等.五酯胶囊对器官移植病人他
tion of tacrolimus in renal transplant recipients[J]. J Clin 克莫司稳态谷浓度影响的定量分析[J].中国临床药理学
Pharm Ther，2017，42（1）：93-97. 与治疗学，2016，21（10）：1132-1136.
[ 5 ] ZHANG X，LIN G，TAN L，et al. Current progress of ta- [19] ZHANG H，BU F，LI L，et al. Prediction of drug-drug in-
crolimus dosing in solid organ transplant recipients：phar- teraction between tacrolimus and principal ingredients of
macogenetic considerations[J]. Biomed Pharmacother， wuzhi capsule in chinese healthy volunteers using physio-
2018. DOI：10.1016/j.biopha.2018.03.054. logically-based pharmacokinetic modelling[J]. Basic Clin
[ 6 ] 李嘉丽，黄民.器官移植术后免疫抑制剂的药物基因组学 Pharmacol Toxicol，2018，122（3）：331-340.
研究进展[J].药学进展，2018，42（4）：243-258. [20] CHEN TQ，LIN MW，LU JW. Hyperkalemia induced by
[ 7 ] JOHNE A，KOPKE K，GERLOFF T，et al. Modulation of tacrolimus combined with Wuzhi-capsule following renal
steady-state kinetics of digoxin by haplotypes of the P-gly-
transplantation：one case report[J]. J Clin Rehab Tissue
coprotein MDR1 gene[J]. Clin Pharmacol Ther，2002，72 Eng Res，2019，15（44）：8341-8343.
（5）：584-594. [21] VAN GELDER T. Drug Interactions with tacrolimus[J].
[ 8 ] RIEGERSPERGER M，PLISCHKE M，STEINHAUSER C，
Drug Safety，2002，25（10）：707-712.
et al. The effect of ABCB1 polymorphisms on serial tacro- [22] Kidney Disease：Improving Global Outcomes（KDIGO）
limus concentrations in stable austrian long-term kidney
Transplant Work Group. KDIGO clinical practice guide-
transplant recipients[J]. Clin Lab，2016，62（10）：1965-
line for the care of kidney transplant recipients[J]. Am J
1972. Transplant，2009，9（S3）：S1-S155.
[ 9 ] PANDEY AV，FLUCK CE. NADPH P 450 oxidoreductase：
structure，function，and pathology of diseases[J]. Pharma- [23] WANG P，MAO Y，RAZO J，et al. Using genetic and clini-
cal factors to predict tacrolimus dose in renal transplant re-
col Ther，2013，138（2）：229-254.
[10] Li L，Li CJ，ZHENG L，et al. Tacrolimus dosing in Chi- cipients[J]. Pharmacogenomics，2010，11（10）：1389-1402.
nese renal transplant recipients：a population-based phar- [24] MENDES J，MARTINHO A，SIMOES O，et al. Genetic
polymorphisms in CYP3A5 and MDR1 genes and their
macogenetics study[J]. Eur J Clin Pharmacol，2011，67
（8）：787-795. correlations with plasma levels of tacrolimus and cyclo-
[11] OETTING W，WU B，SCHLADT DP，et al. Attempted sporine in renal transplant recipients[J]. Transplant Proc，
2009，41（3）：840-842.
validation of 44 reported SNPs associated with tacrolimus
troughs in a cohort of kidney allograft recipients[J]. Phar- [25] 刘其雨，李立，李晓延，等. ABCB1基因多态性对肝移植
macogenomics，2018，19（3）：175-184. 后他克莫司用量的影响[J].中国组织工程研究与临床康
复，2011，15（31）：5717-5721.
[12] LI CJ，LI L，LIN L，et al. Impact of the CYP3A5，CYP3A4，
COMT，IL-10 and POR genetic polymorphisms on tacroli- [26] GENVIGIR FDV，NISHIKAWA AM，FELIPE CR，et al.
mus metabolism in Chinese renal transplant recipients[J]. Inflfluence of ABCC2，CYP2C8，and CYP2J2 polymor-
PLoS One，2014. DOI：10.1371/journal.pone.0086206. phisms on tacrolimus and mycophenolate sodium-based
[13] BARRACLOUGH KA，ISBEL NM，LEE KJ，et al. NR1I2 treatment in Brazilian kidney transplant recipients[J].
polymorphisms are related to tacrolimus dose-adjusted ex- Pharmacotherapy，2017，37（5）：535-545.
posure and BK viremia in adult kidney transplantation[J]. [27] ZHANG JJ，LIU SB，XUE L，et al. The genetic polymor-
Transplant J，2012，94（10）：1025-1032. phisms of POR*28 and CYP3A5*3 significantly influence
[14] KLEIN K，THOMAS M，WINTER S，et al. PPARA：a the pharmacokinetics of tacrolimus in Chinese renal trans-
novel genetic determinant of CYP3A4 in vitro and in vi- plant recipients[J]. Int J Clin Pharmacol Ther，2015，53
vo[J]. Clin Pharmacol Ther，2012，91（6）：1044-1052. （9）：728-736.
[15] LIU MZ，HE HY，ZHANG YL，et al. IL-3 and CTLA4 [28] LI JL，LIU S，FU Q，et al. Interactive effects of CYP3A4，
gene polymorphisms may influence the tacrolimus dose re- CYP3A5，MDR1 and NR1I2 polymorphisms on tracrolim-
quirement in Chinese kidney transplant recipients[J]. Acta us trough concentrations in early postrenal transplant re-
Pharmacol Sin，2017，38（3）：415-423. cipients[J]. Pharmacogenomics，2015，16（12）：1-11.
[16] HOSOHATA K，MASUDA ST，TAKADA Y，et al. Impact [29] 陈礼治，张义，焦正，等.五味子提取物制剂对他克莫司药

中国药房 2020年第31卷第4期 China Pharmacy 2020 Vol. 31 No. 4 ·483 ·